Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PHA-665752 |
Synonyms | |
Therapy Description |
PHA-665752 is a small molecule inhibitor of MET, which inhibits MET kinase activity and downstream signaling, potentially resulting in increased apoptosis and decreased proliferation and migration of tumor cells (PMID: 14612533, PMID: 29456739). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PHA-665752 | PHA665752|PHA 665752 | MET Inhibitor 59 | PHA-665752 is a small molecule inhibitor of MET, which inhibits MET kinase activity and downstream signaling, potentially resulting in increased apoptosis and decreased proliferation and migration of tumor cells (PMID: 14612533, PMID: 29456739). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR1 pos FGFR2 pos | hepatocellular carcinoma | no benefit | PHA-665752 | Preclinical - Cell culture | Actionable | In a preclinical study, PHA-665752 treatment did not result in decreased colony formation or reduced phosphorylation levels of FGFR1 and FGFR2 in hepatocellular carcinoma cells in culture (PMID: 26351320). | 26351320 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|